Autoimmunity and Cancer—Two Sides of the Same Coin

Sakowska, Justyna; Arcimowicz, Łukasz; Jankowiak, Martyna; Papak, Ines; Markiewicz, Aleksandra; Dziubek, Katarzyna; Kurkowiak, Małgorzata; Kote, Sachin; Kaźmierczak-Siedlecka, Karolina; Połom, Karol; Marek-Trzonkowska, Natalia; Trzonkowski, Piotr

doi:10.3389/fimmu.2022.793234

Cited by 30 publications

(20 citation statements)

References 371 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from lymphocytes, T and some B cell subpopulations are active in autoimmunity. These are among others: memory B cells, regulatory B cells (Bregs) and transitional B cells (trBcells) [ 57 , 69 , 70 ]. The pattern of the cytokine network in the context of cellular immune response is very important.…”

Section: Pathogenesis and Common Pathwaysmentioning

confidence: 99%

“…It is rational to suspect that a plethora of neoantigens and products of cell damage could activate autoreactivity [ 72 ]. However, the specific cellular and humoral elements of immune reaction in autoimmunity and cancer are at two poles [ 69 ]. Thus, this aspect of immune response in COPD/lung cancer patients is of great interest.…”

Section: Pathogenesis and Common Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Lung Cancer in the Course of COPD-Emerging Problems Today

Uliński

Kwiecień

Domagała‐Kulawik

2022

Cancers

View full text Add to dashboard Cite

Tobacco smoking remains the main cause of tobacco-dependent diseases like lung cancer, chronic obstructive pulmonary disease (COPD), in addition to cardiovascular diseases and other cancers. Whilst the majority of smokers will not develop either COPD or lung cancer, they are closely related diseases, occurring as co-morbidities at a higher rate than if they were independently triggered by smoking. A patient with COPD has a four- to six-fold greater risk of developing lung cancer independent of smoking exposure, when compared to matched smokers with normal lung function. The 10 year risk is about 8.8% in the COPD group and only 2% in patients with normal lung function. COPD is not a uniform disorder: there are different phenotypes. One of them is manifested by the prevalence of emphysema and this is complicated by malignant processes most often. Here, we present and discuss the clinical problems of COPD in patients with lung cancer and against lung cancer in the course of COPD. There are common pathological pathways in both diseases. These are inflammation with participation of macrophages and neutrophils and proteases. It is known that anticancer immune regulation is distorted towards immunosuppression, while in COPD the elements of autoimmunity are described. Cytotoxic T cells, lymphocytes B and regulatory T cells with the important role of check point molecules are involved in both processes. A growing number of lung cancer patients are treated with immune check point inhibitors (ICIs), and it was found that COPD patients may have benefits from this treatment. Altogether, the data point to the necessity for deeper analysis and intensive research studies to limit the burden of these serious diseases by prevention and by elaboration of specific therapeutic options.

show abstract

Section: Pathogenesis and Common Pathwaysmentioning

confidence: 99%

Section: Pathogenesis and Common Pathwaysmentioning

confidence: 99%

Lung Cancer in the Course of COPD-Emerging Problems Today

Uliński

Kwiecień

Domagała‐Kulawik

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Immunosubversion is the prime immune functional defect in cancer pathogenesis [1], while hyperactivation of the immune system against self-antigens is the main pathogenic alteration in autoimmune pathogenesis [2]. This contrasting immune landscape between autoimmunity and cancer is mainly explained by immunological tolerance [3]. Autoreactive immune cells escaping from the central tolerance mechanism and impaired peripheral tolerance are the hallmarks of autoimmunity.…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, blocking the CTLA-4 by Anti-CTLA-4 antibodies was shown to remove the immune barrier to cancer and demonstrated as promising cancer therapy [19]. Furthermore, many proinflammatory and immunosuppressive cytokines are found to be increased or decreased in an opposite manner between cancer and autoimmunity, such as IL-10 and TGF-beta [3]. However, the presence of opposite immune landscape between autoimmunity and cancer is not always constant.…”

Section: Introductionmentioning

confidence: 99%

Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis

Islam

Tran

et al. 2022

Microbiome

View full text Add to dashboard Cite

Background The gut microbiome promotes specific immune responses, and in turn, the immune system has a hand in shaping the microbiome. Cancer and autoimmune diseases are two major disease families that result from the contrasting manifestations of immune dysfunction. We hypothesized that the opposing immunological profiles between cancer and autoimmunity yield analogously inverted gut microbiome signatures. To test this, we conducted a systematic review and meta-analysis on gut microbiome signatures and their directionality in cancers and autoimmune conditions. Methodology We searched PubMed, Web of Science, and Embase to identify relevant articles to be included in this study. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements and PRISMA 2009 checklist. Study estimates were pooled by a generic inverse variance random-effects meta-analysis model. The relative abundance of microbiome features was converted to log fold change, and the standard error was calculated from the p-values, sample size, and fold change. Results We screened 3874 potentially relevant publications. A total of 82 eligible studies comprising 37 autoimmune and 45 cancer studies with 4208 healthy human controls and 5957 disease cases from 27 countries were included in this study. We identified a set of microbiome features that show consistent, opposite directionality between cancers and autoimmune diseases in multiple studies. Fusobacterium and Peptostreptococcus were the most consistently increased genera among the cancer cases which were found to be associated in a remarkable 13 (+0.5 log fold change in 5 studies) and 11 studies (+3.6 log fold change in 5 studies), respectively. Conversely, Bacteroides was the most prominent genus, which was found to be increased in 12 autoimmune studies (+0.2 log fold change in 6 studies) and decreased in six cancer studies (−0.3 log fold change in 4 studies). Sulfur-metabolism pathways were found to be the most frequent pathways among the member of cancer-increased genus and species. Conclusions The surprising reproducibility of these associations across studies and geographies suggests a shared underlying mechanism shaping the microbiome across cancers and autoimmune diseases.

show abstract

“…It was found in a study of COVID-19 that SARS-CoV-2 infection in primates was also associated with altered intestinal flora composition and functional activity ( 33 ). Thus, dysregulation of the microbiome has been related to systemic inflammatory disease ( 34 , 35 ) and various types of cancer ( 36 ). In addition, intestinal flora also influence the effectiveness of chemotherapy in cancer patients ( 37 , 38 ), which means maintaining a good intestinal flora plays an important role in the treatment of diseases ( 39 ).…”

Section: Introductionmentioning

confidence: 99%

Antitumor effects of polysaccharides from Tetrastigma hemsleyanum Diels et Gilg via regulation of intestinal flora and enhancing immunomodulatory effects in vivo

Zhou

Sun

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tetrastigma hemsleyanum Diels et Gilg is a traditional Chinese herbal medicine with high medicinal value, and antitumor, antioxidant and anti-inflammatory biological activities. However, while several studies have focused on flavonoids in Tetrastigma hemsleyanum tubers, there are few studies on the enhanced immune effect of Tetrastigma hemsleyanum polysaccharides (THP). In this study, we evaluated the antitumor effect of THP in a lung tumor model and explored the mechanism of antitumor activity through intestinal flora. In addition, a cyclophosphamide (CTX)-induced immunosuppression model was used to declare the immunomodulatory effect of THP in the immunosuppressive state induced by antitumor drugs. The results showed that THP increased the content of ileum secreted immunoglobulin A (SIgA) and cecum short-chain fatty acids (SCFAs) and improved microbial community diversity, regulating the relative abundance of dominant microbiota flora from the phylum level to the genus level, and recovering the intestinal microflora disorder caused by tumors. Additionally, THP can increase the organ indices and improve immune organ atrophy. THP can upregulate routine blood counts and stimulate the production of the serum cytokines. THP also promoted the macrophage phagocytic index, NK-cell activation, and complement and immunoglobulin (IgG, IgA, IgM) levels. The detection of Splenic lymphocyte proliferation and T lymphocyte subsets also sideways reflects that THP can restore CTX-induced immune inhibition in mice. In conclusion, this study suggests that THP can effectively achieve the enhanced antitumor effects, regulate gut microbiota and improve the immunosuppression induced by antitumor drugs. Therefore, THP can enhance the immune capacity and provide novel immunomodulatory and antineoplastic adjuvant agents.

show abstract

Autoimmunity and Cancer—Two Sides of the Same Coin

Cited by 30 publications

References 371 publications

Lung Cancer in the Course of COPD-Emerging Problems Today

Lung Cancer in the Course of COPD-Emerging Problems Today

Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis

Antitumor effects of polysaccharides from Tetrastigma hemsleyanum Diels et Gilg via regulation of intestinal flora and enhancing immunomodulatory effects in vivo

Contact Info

Product

Resources

About